ID | 46629 |
JaLCDOI | |
FullText URL | |
Author |
Teramen, Hirotake
Tanaka, Norimitsu
Ueno, Tsuyoshi
Kubo, Takafumi
Ando, Midori
Asano, Hiroaki
Pass, Harvery I.
Toyooka, Shinichi
|
Abstract | Suppression of p21 has been implicated in the genesis and progression of many human malignancies. DNA methylation is an important mechanism of gene silencing in human malignancies. In this study, we examined the expression status and aberrant methylaion of p21 in lung cancers and malignant pleural mesotheliomas (MPM). We used 12 small cell lung cancer (SCLC) cell lines, 13 non-small cell lung cancer (NSCLC) cell lines, 50 primary NSCLCs, 6 MPM cell lines and 10 primary MPMs. The expression and methylation of p21 was examined by reverse transcription-PCR (RT-PCR), Western blotting and methylation-specific PCR (MSP) assay. Loss of p21 protein expression was observed in 7 SCLC cell lines (58.3%), 5 NSCLC cell lines (38.5%) and 3 MPM cell lines (50%) while mRNA expression was lost in 2 SCLC cell lines (16.7%), 2 NSCLC cell lines (15.4%) and none of the MPM cell lines. Aberrant methylation of p21 was found in 8.3% of SCLC cell lines, 30.2% of NSCLCs and 6.3% of MPMs. Among primary NSCLCs, methylation in adenocarcinomas was significantly more frequent than in squamous cell carcinomas. Loss of p21 expression was frequently observed in lung cancers and MPMs and aberrant methylation was one of the mechanisms of suppression of p21, especially in NSCLCs.
|
Keywords | p21
methylation
lung cancer
mesothelioma
|
Amo Type | Original Article
|
Publication Title |
Acta Medica Okayama
|
Published Date | 2011-06
|
Volume | volume65
|
Issue | issue3
|
Publisher | Okayama University Medical School
|
Start Page | 179
|
End Page | 184
|
ISSN | 0386-300X
|
NCID | AA00508441
|
Content Type |
Journal Article
|
language |
English
|
Copyright Holders | CopyrightⒸ 2011 by Okayama University Medical School
|
File Version | publisher
|
Refereed |
True
|
PubMed ID | |
Web of Science KeyUT |